ISV 616

Drug Profile

ISV 616

Latest Information Update: 24 Apr 2007

Price : $50

At a glance

  • Originator InSite Vision
  • Class
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Diabetic retinopathy; Macular degeneration

Most Recent Events

  • 20 Aug 2003 This compound is still in active development
  • 10 Sep 2001 Preclinical development for Macular degeneration in USA (Ophthalmic)
  • 10 Sep 2001 Preclinical development for Diabetic retinopathy in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top